A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial

OBJECTIVE: Pharmacogenomic-based antidepressant treatment (PGATx) may result in more precise pharmacotherapy of major depressive disorder (MDD) with better drug therapy guidance. METHODS: An 8-week, randomized, single-blind clinical trial was conducted to evaluate the effectiveness and tolerability...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Psychopharmacol Neurosci
Autors principals: Han, Changsu, Wang, Sheng-Min, Bahk, Won-Myong, Lee, Soo-Jung, Patkar, Ashwin A., Masand, Prakash S., Mandelli, Laura, Pae, Chi-Un, Serretti, Alessandro
Format: Artigo
Idioma:Inglês
Publicat: Korean College of Neuropsychopharmacology 2018
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6245286/
https://ncbi.nlm.nih.gov/pubmed/30466219
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.9758/cpn.2018.16.4.469
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars